EURONEXT Aktie

 

Reference is made to the stock exchange announcement made by Nordic Mining ASA (the "Company") on 16 January 2026, regarding key information relating to a potential subsequent repair offering of new shares in the Company (the "Subsequent Offering"). The shares in Company will be traded exclusive of the right to participate in the Subsequent Offering from and including today, 16 January 2026. Ex. date: 16 January 2026 This information is published in accordance with the rules of Euronext Oslo Børs....

Aalst, Belgium, January 14, 2026 – Ontex Group NV (Euronext: ONTEX), a leading international developer and producer of personal care solutions, has received an 'A' rating for the second year in a row from CDP, the global environmental non-profit, for its leadership in corporate transparency and performance on climate change....

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial....

Sandnes, Norway, 9 January 2026: The board of directors of Vår Energi (OSE: VAR, the “Company”) hereby calls for an extraordinary general meeting (“EGM”) to be held on 30 January 2026 at 15:00 CET to approve a dividend for the fourth quarter of 2025, based on the Company's audited interim balance sheet and notes as per 30 September 2025. Shareholders can participate in the EGM via webcast and also vote in advance or by proxy. The deadline for advance voting and proxy registration is 28 January 2026 at 15:00 CET. Only shareholders registered in Euronext VPS as of 23 January 2026 are entitled...

Euronext announces volumes for December 2025...

Full and original release on www.actusnews.com. Subscribe to this company's information....

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026....

For the first time since Euronext NV's own initial public offering more than a decade ago, companies raised less than $1 billion through IPOs across its exchanges in 2025, bearing the brunt of the continent's capital markets stagnation....

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 6, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that G1090N – a small molecule and the Company's lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile, and a strong anti-inflammatory activity in ex-vivo studies....

Half-year statement of the liquidity contract of Euronext NV...

January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT....

Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities....

Zentraler europäischer Aktienhandel in Frankfurt? Wie realistisch die Pläne von Merz, Rhein und der CSU sind....

Die zersplitterte Börsenlandschaft in Europa gilt als Wettbewerbsnachteil gegenüber den USA. Um Unternehmen in Deutschland zu halten, will sich nun auch die CSU für eine europäische Börse einsetzen....

Louvain-La-Neuve, Belgium, December 26, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Catholic University of Korea, Seoul St. Mary's Hospital, one of the largest hospital in South Korea, for a Proteus®PLUS1 solution to be installed in Seoul....

December 22, 2025 – Aker Solutions ASA (“Aker Solutions”) has today allocated shares to primary insiders participating in the company's employee share purchase program for 2025. Reference is made to the stock exchange release published earlier today, December 22, 2025, concerning the employee share purchase program and share allocation. For the December 2025 allocation, shares were sold at a price per share, excluding applicable discount, of NOK 30.1532 which equals the volume-weighted average share price of Aker Solutions on Euronext Oslo Børs from and including December 15, 2025, to and...

Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium....

Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11,  The Lancet – one of the world's most renowned  academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderson Cancer Center, the world's leading hospital for cancer care, is the first-ever randomized controlled trial (RCT) to provide the highest level of evidence demonstrating the benefits of proton therapy over conventional radiotherapy for this indication....

STAMFORD, Conn.--(BUSINESS WIRE)--Es wird auf die Börsenmitteilung von SmartCraft ASA („SmartCraft” oder das „Unternehmen”) vom 1. Dezember 2025 bezüglich der geplanten Umnotierung von SmartCraft von der Euronext Oslo Børs an die Nasdaq Stockholm (die „Umnotierung”) und die Ankündigung einer grenzüberschreitenden Fusion zur Durchführung der Umnotierung verwiesen. Die von Anabranch Capital Management, LP („Anabranch“) verwalteten Fonds beabsichtigen, für den von den Vorständen von SmartCraft und seiner schwedischen hundertprozentigen Tochtergesellschaft SmartCraft Group AB (publ) beschlossenen Fusionsplan zu stimmen, um die Wiederaufnahme der Notierung auf der für Januar 2025 geplanten außerordentlichen Hauptversammlung der Gesellschaft (die „EGM“) zu erreichen. Anabranch beabsichtigt, mit allen Anabranch-Aktien, die zum Stichtag für die außerordentliche Hauptversammlung gehalten werden, für die durch den Fusionsplan bewirkte Wiederaufnahme der Börsennotierung zu stimmen. ...

STAMFORD, Conn.--(BUSINESS WIRE)--Reference is made to the stock exchange announcement by SmartCraft ASA ("SmartCraft" or the "Company") on 1 December 2025 regarding the contemplated relisting of SmartCraft from Euronext Oslo Børs to Nasdaq Stockholm (the "Relisting") and the announcement of a cross-border merger to effect the Relisting. Funds managed by Anabranch Capital Management, LP (“Anabranch”) intend to vote in favour of the merger plan resolved by the boards of SmartCraft and its Swedish wholly owned subsidiary, SmartCraft Group AB (publ), to effect the Relisting at the Company's extraordinary general meeting planned for January 2025 (the "EGM"). Anabranch intends to vote with all Anabranch shares held at the Record Date for the EGM in favour of the relisting effected by the merger plan. Funds managed by Anabranch currently hold approximately 15.9 million shares in SmartCraft. Disclaimer: The views expressed are those of the authors and Anabranch Capit...